PADI4 and COVID-19: NETs have been implicated in COVID-19 pathogenesis [20] and the ability for a PAD inhibitor to block the formation of citrullinated histones may offer therapeutic benefit to both the thrombotic and inflammatory effects observed in the viral infection.